Skip to contentE
Emergent BioSolutions Inc.
E
EBSEmergent BioSolutions Inc. Q1 2021 · 10-Q
Revenue$343.00M$343.00M+78.2% vs Q1 2020 Net Income$67.30M$67.30MN/M vs Q1 2020 EPS Diluted$1.23$1.23N/M vs Q1 2020 Gross Profit$222,400,000— Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
Operating Cash Flow$5,100,000−91.2% Free Cash Flowderived-$51,000,000N/M Margins · derivedGross margin64.8%
Operating margin26.9%+32.9 pt vs Q1 2020
Net margin19.6%+26.1 pt vs Q1 2020
ended Mar 31, 2021 · filed Apr 30, 2021 · 30 d after period end